HIV: First-in-Class Therapies Target Major Unmet Needs Including Drug Resistance and Latency Reversal

  • RnM3875473
  • |
  • 05 February, 2020
  • |
  • 63 Pages
  • |
  • GlobalData
  • |
  • Pharma & Healthcare

Check Discount on this report



Purchase this Report

$6,995.00
$13,990.00
$20,985.00
5,679.94
11,359.88
17,039.82
6,722.20
13,444.39
20,166.59
1,088,631.85
2,177,263.70
3,265,895.55
605,417.25
1,210,834.50
1,816,251.75
Credit card Logo